Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shnehal Patel"'
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 7, Iss , Pp 100153- (2022)
Dopamine agonist withdrawal syndrome (DAWS) has been introduced to describe the constellation of symptoms resulting from reduction or suspension of dopamine agonist medications. In patients with Parkinson’s disease (PD) the impact of DAWS can be si
Externí odkaz:
https://doaj.org/article/23980e6ad51240ce83a0a6567e966304
Autor:
Mohammad Edrees Mohammad, Joaquin A. Vizcarra, Xiomara Garcia, Shnehal Patel, Adam Margolius, Xin Xin Yu, Hubert H. Fernandez
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 4, Iss , Pp 100091- (2021)
Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral. Behavioral side effects include: impulse control behavio
Externí odkaz:
https://doaj.org/article/dd20675f880a4cb1964cb8c0295fa9b3
Autor:
Xiomara Garcia, Mohammad Edrees Mohammad, Shnehal Patel, Adam Margolius, Joaquin A. Vizcarra, Hubert H. Fernandez, Xin Xin Yu
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 4, Iss, Pp 100091-(2021)
Clinical Parkinsonism & Related Disorders
Clinical Parkinsonism & Related Disorders
Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral. Behavioral side effects include: impulse control behavio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe7cdd21d59bee29f7a386b10cb73ca
http://www.sciencedirect.com/science/article/pii/S2590112521000037
http://www.sciencedirect.com/science/article/pii/S2590112521000037
Autor:
Lu Wang, James Bena, Srivadee Oravivattanakul, Anwar Ahmed, Hubert H. Fernandez, Gençer Genç, Tanaporn Rasameesoraj, Shnehal Patel, Michelle Drerup, Oluwadamilola O. Ojo, Nancy Foldvary-Schaefer, Yang Huo
Publikováno v:
Journal of Clinical Movement Disorders, Vol 4, Iss 1, Pp 1-7 (2017)
Journal of Clinical Movement Disorders
Journal of Clinical Movement Disorders
Background Parkinson disease (PD) is associated with a high prevalence of insomnia, affecting up to 88% of patients. Pharmacotherapy studies in the literature addressing insomnia in PD reveal disappointing and inconsistent results. Cognitive behavior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd17f368f238a286643505f400a4eefe
http://link.springer.com/article/10.1186/s40734-017-0062-2
http://link.springer.com/article/10.1186/s40734-017-0062-2
Autor:
Carol Hennessy, Thien Thien Lim, Ramon L. Rodriguez, Shnehal Patel, Oluwadamilola O. Ojo, Hubert H. Fernandez, Irene A. Malaty, Benjamin Nutter, Yogesh Gujrati, Rafael Palacio, Benzi M. Kluger, Camille Swartz
Publikováno v:
Movement Disorders. 30:1825-1830
Background Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments. Methods In this double-blinded, placebo-controlled, pilot trial, we investigated whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59cbdeffbf170337eba21638b225e788
https://doi.org/10.1002/mds.26429
https://doi.org/10.1002/mds.26429
Autor:
Kaley O'Donnell, Mohammad Edrees Mohammad, Kathryn Sutton, Katelyn Vlastaris, Xiomara Garcia, Xin Xin Yu, Shnehal Patel, Hubert H. Fernandez
Publikováno v:
Journal of the neurological sciences. 379
Introduction Dopamine agonists are a mainstay of treatment for patients with Parkinson disease (PD). However, side effects limit their use, often necessitating dose change. Upon withdrawal, patients may experience dopamine agonist withdrawal syndrome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d54bb034cf9ee7be9a831f2564ed102
https://pubmed.ncbi.nlm.nih.gov/28716269
https://pubmed.ncbi.nlm.nih.gov/28716269
Publikováno v:
Neuro-Geriatrics ISBN: 9783319564838
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::316c9e7035f9e5a16b5d765a0af88f34
https://doi.org/10.1007/978-3-319-56484-5_10
https://doi.org/10.1007/978-3-319-56484-5_10
Autor:
Thien Thien, Lim, Benzi M, Kluger, Ramon L, Rodriguez, Irene A, Malaty, Rafael, Palacio, Oluwadamilola O, Ojo, Shnehal, Patel, Yogesh, Gujrati, Benjamin, Nutter, Camille, Swartz, Carol, Hennessy, Hubert H, Fernandez
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 30(13)
Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments.In this double-blinded, placebo-controlled, pilot trial, we investigated whether rasagiline improved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2e1d39e7903c00fecffb14795273dc2d
https://pubmed.ncbi.nlm.nih.gov/26769459
https://pubmed.ncbi.nlm.nih.gov/26769459
Autor:
Mohammad Ali Aziz-Sultan, Efrat Saraf-Lavi, Dileep R. Yavagal, Shnehal Patel, Jeremiah N. Johnson
Publikováno v:
Journal of NeuroInterventional Surgery. 7:e23-e23
Posterior spinal artery (PSA) aneurysms are a rare cause of subarachnoid hemorrhage (SAH). The commonly abused street drug 3,4-methylenedioxymethamphetamine (MDMA) or ‘Ecstasy’ has been linked to both systemic and neurological complications. A te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e68716b6b10e4af066e9102546ca4432
https://doi.org/10.1136/neurintsurg-2014-011248.rep
https://doi.org/10.1136/neurintsurg-2014-011248.rep